Clinical Trial Update: AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study update of AZD6244 (ARRY-142886) in adults with advanced solid malignancies; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• AZD6244 (ARRY-142886) (selumetinib)

Snippet

Sponsor: AstraZeneca | Conditions: Tumor, Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING